Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide and Nivolumab in Virus-Associated Malignancies
NCT04902443Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Dec 2021
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label trial of pomalidomide and nivolumab in virus-associated malignancy (3 arms), sponsored by National Cancer Institute. Primary endpoint: Safety and tolerability of pomalidomide with nivolumab at 24 months. Started Dec 2021; status: recruiting.
02
Drugs
pomalidomidenivolumab
03
Conditions
virus-associated malignancy
Beyond the preview
Go deeper on NCT04902443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04902443.